BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8530001)

  • 1. Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.
    Férec C; Verlingue C; Parent P; Morin JF; Codet JP; Rault G; Dagorne M; Lemoigne A; Journel H; Roussey M
    Hum Genet; 1995 Nov; 96(5):542-8. PubMed ID: 8530001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
    Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
    BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
    Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
    BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
    Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
    Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis.
    Scotet V; De Braekeleer M; Audrézet MP; Lodé L; Verlingue C; Quéré I; Mercier B; Duguépéroux I; Codet JP; Moineau MP; Parent P; Férec C
    Clin Genet; 2001 Jan; 59(1):42-7. PubMed ID: 11168024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk calculations for cystic fibrosis in neonatal screening by immunoreactive trypsinogen and CFTR mutation tests.
    Ogino S; Flodman P; Wilson RB; Gold B; Grody WW
    Genet Med; 2005; 7(5):317-27. PubMed ID: 15915083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.
    Massie J; Curnow L; Tzanakos N; Francis I; Robertson CF
    Arch Dis Child; 2006 Mar; 91(3):222-5. PubMed ID: 16243854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Neonatal screening for cystic fibrosis].
    Tellería Orriols JJ; Alonso Ramos MJ; Garrote Adrados JA; Fernández Carvajal I; Blanco Quirós A
    An Esp Pediatr; 2002 Jul; 57(1):60-5. PubMed ID: 12139895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.
    Lecoq I; Brouard J; Laroche D; Férec C; Travert G
    Acta Paediatr; 1999 Mar; 88(3):338-41. PubMed ID: 10229049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newborn screening for cystic fibrosis in Switzerland--consequences after analysis of a 4 months pilot study.
    Torresani T; Fingerhut R; Rueegg CS; Gallati S; Kuehni CE; Baumgartner MR; Barben J;
    J Cyst Fibros; 2013 Dec; 12(6):667-74. PubMed ID: 23712087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
    Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for cystic fibrosis in New York State: considerations for algorithm improvements.
    Kay DM; Maloney B; Hamel R; Pearce M; DeMartino L; McMahon R; McGrath E; Krein L; Vogel B; Saavedra-Matiz CA; Caggana M; Tavakoli NP
    Eur J Pediatr; 2016 Feb; 175(2):181-93. PubMed ID: 26293390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.